Board of Governors of the Federal Reserve System, November 14, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96-29600 Filed 11-19-96; 8:45 am]

BILLING CODE 6210-01-F

Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 4, 1996.

A. Federal Reserve Bank of Cleveland (R. Chris Moore, Senior Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. Mid Am, Inc., Bowling Green, Ohio; to engage de novo through its subsidiary, Mid Am Private Trust, National Association, Cincinnati, Ohio, in performing functions or activities of a trust company, pursuant to § 225.25(b)(3) of the Board's Regulation Y.

B. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

 Southern National Corporation, Winston-Salem, North Carolina, and BB&T Financial Corporation of Virginia, Virginia Beach, Virginia; to acquire Fidelity Financial Bankshares Corporation, Richmond, Virginia, and thereby indirectly acquire Fidelity Federal Savings Bank, Richmond, Virginia, and thereby engage in operating a savings institution, pursuant to § 225.25(b)(9) of the Board's Regulation Y, and in holding limited partnership interests in funds that invest in partnerships which own and operate low income rental properties, pursuant to § 225.25(b)(6) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, November 14, 1996. William W. Wiles.

Secretary of the Board.

[FR Doc. 96–29601 Filed 11-19-96; 8:45 am] BILLING CODE 6210-01-F

Sunshine Act Meeting Notice

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11:00 a.m., Monday, November 25, 1996.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed. MATTERS TO BE CONSIDERED:

- 1. Federal Reserve Bank and Branch director appointments.
- 2. Proposed procedural amendments to the Federal Reserve System Retirement Plan.
- 3. Proposed acquisition of automated data processing equipment within the Federal Reserve System.
- Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
- 5. Any items carried forward from a previously announced meeting.

Contact Person for More Information: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: November 15, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96–29764 Filed 11–18–96; 10:35

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N-0279]

Agri-Tech, Inc.; Proposal To Withdraw Approval of a New Animal Drug Application; Opportunity for a Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing an opportunity for a hearing on a proposal to withdraw approval of a new animal drug application (NADA) for Protamone-D (iodinated casein tablets), held by Agri-Tech, Inc., because the applicant has failed to submit required periodic reports.

DATES: Requests for a hearing with data, analysis, and information relied upon to justify a request for a hearing are due by December 20, 1996.

ADDRESSES: Requests for a hearing, supporting data, and other comments filed in response to this notice should be identified with Docket No. 96N–0279 and sent to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Mohammad I. Sharar, Center for Veterinary Medicine (HFV–216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827– 0159. SUPPLEMENTARY INFORMATION: An

applicant is required to report periodically to the Center for Veterinary Medicine (CVM) concerning each of the applicant's approved NADA's as provided in § 510.300 (21 CFR 510.300). Agri-Tech, Inc., 4722 Broadway, Kansas City, MO 64112 (last known address), is the sponsor of NADA 13–502 which provides for oral use of Protamone-D (iodinated casein tablets) in dogs. Agri-Tech, Inc., has not submitted the required periodic reports for NADA 13–502 and has not responded to CVM's requests for submission of those reports. Letters to the firm have been returned

indicating the firm is no longer at the

above-listed address.